Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by Beijing Northland Biotech. Co., Ltd..
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
ViroMed Co., Ltd. dba VM BioPharma
Information provided by (Responsible Party):
Beijing Northland Biotech. Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01548378
First received: March 5, 2012
Last updated: April 9, 2012
Last verified: March 2012

March 5, 2012
April 9, 2012
March 2012
June 2013   (final data collection date for primary outcome measure)
  • The difference in ulcer area between baseline and the D180. [ Time Frame: Day180 ] [ Designated as safety issue: No ]
  • The difference in pain level between baseline and the D180 as determined by VAS [ Time Frame: Day 180 ] [ Designated as safety issue: No ]
  • To assess the difference in ulcer area between baseline and the D180. [ Time Frame: Day180 ] [ Designated as safety issue: No ]
  • To assess the difference in pain level between baseline and the D180 as determined by VAS [ Time Frame: Day 180 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01548378 on ClinicalTrials.gov Archive Site
  • Change in tissue oxygenation (TcPO2) from baseline to D180 [ Time Frame: Day0、14、28、60、90、180 ] [ Designated as safety issue: No ]
  • Difference in percentage of pain level decreased by 50% determined by VAS from baseline to D180 [ Time Frame: Day0、14、28、60、90、180 ] [ Designated as safety issue: No ]
  • Difference in percentage of ulcer area decreased by 50% from baseline to D180 [ Time Frame: Day0、14、28、60、90、180 ] [ Designated as safety issue: No ]
  • Difference in ABI and TBI from baseline to D180 [ Time Frame: Day0、14、28、60、90、180 ] [ Designated as safety issue: No ]
  • Difference in QOL score (VascuQol) from baseline to D180 [ Time Frame: Day0、14、28、60、90、180 ] [ Designated as safety issue: No ]
  • Percentage of ulcer complete healing [ Time Frame: Day180 ] [ Designated as safety issue: No ]
  • Situation of ulcer healing [ Time Frame: Day180 ] [ Designated as safety issue: No ]
  • Ulcer healing after gangrene treatment [ Time Frame: Day180 ] [ Designated as safety issue: No ]
  • Major amputation rate [ Time Frame: Day180 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia
A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia

The purpose of this study is to evaluate whether intramuscular injections of NL003 into the calf is safe and effective in the treatment of critical limb ischemia

Management of CLI process consumes a significant amount of healthcare resources,and the new therapeutic approaches are required.

Hepatocyte growth factor (HGF) has been shown to be a potent angiogenic growth factor stimulating the growth of endothelial cells and migration of vascular smooth muscle cells. Because of its pluripotent capabilities, increasing the availability of HGF in ischemic tissues to achieve therapeutic angiogenesis has been a growing area of research.

This study will use NL003, which is a DNA plasmid that contains novel genomic cDNA hybrid human HGF coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723. As there are currently no approved drugs that can reverse CLI and as most patients have exhausted surgical and endovascular intervention options, inducing angiogenesis in the affected limb with NL003 may result in an increase in tissue perfusion, which, in turn improve wound healing, reduce pain and improve limb salvage rates.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Ischemia
  • Pathologic Processes
  • Genetic: NL003
    Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
    Other Names:
    • DNA Plasmid
    • HGF-X7
  • Genetic: NL003
    Day 0: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 14: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 28: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections)
    Other Names:
    • DNA Plasmid
    • HGF-X7
  • Genetic: NL003
    Day 0: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 14: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 28: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections)
    Other Names:
    • DNA Plasmid
    • HGF-X7
  • Other: Normal Saline
    Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
    Other Name: Placebo
  • Experimental: High Dose
    Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
    Intervention: Genetic: NL003
  • Experimental: Middle Dose
    Patients in this treatment group will receive 6mg NL003 respective in D0、14、28
    Intervention: Genetic: NL003
  • Experimental: Low Dose
    Patients in this treatment group will receive 4mg NL003 in D0、14、28
    Intervention: Genetic: NL003
  • Sham Comparator: Placebo
    Patients in this group will receive normal saline respective in D0、14、18
    Intervention: Other: Normal Saline
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
200
June 2013
June 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female, between 30 and 80years of age
  • Diagnosis of critical limb ischemia(ASO、TAO、DAO),Rutherford Class 4 or 5, including:

    • A resting ankle systolic pressure of ≤ 70 mmHg in the affected limb; or
    • A resting toe systolic pressure of ≤ 50 mmHg in the affected limb; or
    • For patients in which measurement of ankle systolic pressure is not feasible , TcPO2 ≤ 30mmHg; Only unilateral affected limb receive treatment。
  • Significant stenosis (≥ 75%) of one or more of the following arteries:

superficial femoral, popliteal as verified by angiography(DSA、CTA、MRA) within 12 months prior to enrollment

  • Be willing to maintain current drug therapy for peripheral arterial disease throughout the course of the study
  • Be willing to maintain ulcer treatment
  • Be willing to infertility throughout the course of the study
  • If the subject is of child-bearing potential, she must have a negative urine pregnancy test result prior to study enrollment
  • Tumor screening result is no clinic meaning,including:
  • Signing the informed consent document prior to being subjected to any study related procedures

Exclusion Criteria:

  • Subjects who have undergone a successful revascularization procedure or sympathectomy within 12 weeks prior to study entry.
  • Acute advanced CLI
  • Subjects that will require an amputation in the target leg within 4 weeks, or significant stenosis (≥ 75%) of Aortoiliac
  • Subjects with evidence of active infection or deep ulceration exposing bone or tendon in the extremity planned for treatment
  • Heart Failure with a NYHA classification of III or IV
  • Stroke、myocardial infarction or unstable angina within last 3 months
  • Uncontrolled hypertension defined as sustained systolic blood pressure (SBP) > 180 mmHg or diastolic BP (DBP) > 110 mmHg
  • Ophthalmologic conditions pertinent to proliferative retinopathy or conditions that preclude standard ophthalmologic examination
  • Can not correctly describe the symptoms and feeling
  • Subjects with advanced liver disease including decompensated cirrhosis, jaundice, ascites or bleeding varices
  • Subjects currently receiving immunosuppressive medications chemotherapy, or radiation therapy
  • Positive HIV,active Hepatitis B(determined by HBsAb\ HBcAb\HBsAg) or C infection
  • Specific laboratory values at Screening including: Hemoglobin < 8.0 g/dL, WBC < 3,000 cells per microliter, platelet count <75,000/mm3, AST and/or ALT > 3 times the upper limit of normal or any other clinically significant lab abnormality which in the opinion of the investigator should be exclusionary
  • Elevated PSA unless prostate cancer has been excluded
  • Patients with a recent history (< 5 years) of or new screening finding of malignant neoplasm except basal cell carcinoma or squamous cell carcinoma of the skin (if excised and no evidence of recurrence); patients with family history of colon cancer in any first degree relative are excluded unless they have undergone a colonoscopy in the last 12 months with negative findings
  • Subjects requiring > 100 mg daily of acetylsalicylic acid,COX-2 inhibitor drug(s) or high dose steroids (excepting inhaled steroids)
  • Subjects with any co- morbid conditions likely to interfere with assessment of safety or efficacy or with an estimated life expectancy of less than 12 months
  • History of drug or alcohol abuse / dependence in the past 12 months
  • Use of an investigational drug or treatment in past 3 months
Both
30 Years to 80 Years
No
Contact: dayou Ding, BM +86-10-82890893 dingdayou@northland-bio.com
China
 
NCT01548378
NL003CLI-II
Yes
Beijing Northland Biotech. Co., Ltd.
Beijing Northland Biotech. Co., Ltd.
ViroMed Co., Ltd. dba VM BioPharma
Not Provided
Beijing Northland Biotech. Co., Ltd.
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP